The World Health Organization (WHO) recently published its Global Report on Trends in Prevalence of Tobacco Use 2000-2030. According to the Report, while global progress is inconsistent, 150...
Broughton announces structure change for growth
Dec 16, 2021 | Published by Fiona Brook
Broughton, a global Contract Research Organization rapidly developing its position as a full-service solutions provider to the global life sciences sector, continues its commitment to delivering life-enhancing products to market.
Founder and Chief Executive Officer, Dr Paul Moran, will transition to the role of Executive Chairman to further grow Broughton’s global capacity, focusing on expanding their existing US team. Co-Founder and Chief Scientific Officer, Chris Allen, will be appointed as Chief Executive Officer effective from 1st January 2022. Chief Regulatory Officer, Dr Nveed Chaudhary, will take up the position of Chief Scientific and Regulatory Officer.
Paul Moran commented ‘’Since 2006, our focus has always been to help our clients succeed. With a passion for enhancing societal health and wellbeing, our expertise across harm reduction and next generation products now covers the broad life science industries of pharmaceuticals, nicotine containing products and cannabinoids. This next phase of our expansion is part of our natural evolution to grow capacity and capabilities. I’ll continue to focus my energies on new markets and early initiatives.’’ Paul continued ‘’Chris has been with Broughton 3 weeks longer than me! He’s an outstanding leader, with great vision for the future growth of Broughton.’’
Chris Allen commented, “The recent changes to our management team reflect our continued commitment and ambition to become the most trusted integrated services provider in the world. Our additional investment plans into global operations will enable us to expand our services for clients across the nicotine, pharmaceutical and cannabinoids markets, always with a focus to help clients deliver life-enhancing products to market. I am delighted to take over the CEO role at Broughton. Harm reduction is our guiding principle. We’ve set ambitious targets to deliver Marketing Authorizations/Orders across global markets for our clients. We have over 150 talented individuals across the life sciences team, with a healthy on-boarding program in 2022 for continued growth, that puts us in a strong position to progress on our mission”.
To find out more contact us
Can we help you?
Broughton have deep CRO capabilities and an experienced team of scientific and regulatory professionals to manage full service global regulatory projects. Our knowledge of global regulatory pathways offers significant insights that can be incorporated into your project plans. Our mission is to accelerate safer nicotine-delivery products to market; creating a smoke-free future.
Book a meeting with us today to discuss your requirements.